Lakeshore Biopharma Co Ltd's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Lakeshore Biopharma Co Ltd (LSB) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Lakeshore Biopharma Co Ltd vs Its Competitors
- TTM: Trailing 12-month revenue of 85M vs 1,584M combined for tracked competitors (5.1% combined share).
- Trending: Latest-quarter revenue run-rate is accelerating (+279.3% annualized vs trailing 12 months), vs decelerating (-8.3%) for its tracked peer group.
- Growth: Lakeshore Biopharma Co Ltd generated -19.2% revenue growth year over year in Q4 2024, vs 10,798.6% for its tracked competitors combined.
- Profitability: Its -75.6% net margin compares with -82.7% for the peer group.
- Peer revenue share: Lakeshore Biopharma Co Ltd accounted for 18.2% of combined revenue among its tracked peer group, down from 96.8% a year earlier.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
LSB Sales vs. its Competitors, Q4 2024
Lakeshore Biopharma Co Ltd reported revenue contraction of 19.18 % year on year in Q4 2024, below its competitors' combined revenue growth of 10,798.59 %.
With a net margin of -75.59 %, Lakeshore Biopharma Co Ltd achieved higher profitability than its competitors (-82.70 %).
Lakeshore Biopharma Co Ltd generated 18.21 % of the combined sales of its peer group, down from 96.78 % a year earlier.
Lakeshore Biopharma Co Ltd vs. its Competitors, Q4 2024
Revenue growth, year on year
Net margin
Revenue run-rate vs trailing 12 months
TTM net margin
TTM = trailing twelve months. Run-rate annualizes the latest quarter (×4) and compares it to TTM. In millions of $. High-Confidence Competitors are named as a competitor directly in an SEC filing; Similar-Size Competitors are the closest peers by market-cap rank within the same industry; Similar Growth & Profitability Competitors are the closest peers by combined revenue growth, operating margin and ROIC, all independent of the competitor list.
TTM revenue, latest-quarter run-rate and net income/margin benchmarked across Lakeshore Biopharma Co Ltd and its 4 competitor groupings. Available under Commercial License.
| Entity | TTM Revenue | Rev Run-rate vs TTM |
|---|---|---|
| Lakeshore Biopharma Co Ltd | $12,345M | +12.3% · Accelerating |
| Competitors combined | $12,345M | +12.3% · Accelerating |
| Similar Growth & Profitability (7) | $12,345M | +12.3% · Accelerating |
TTM revenue, run-rate and net margin benchmarking across Lakeshore Biopharma Co Ltd's competitor groups requires a Commercial License.
For context: the Major Pharmaceutical Preparations industry grew revenue 7.2% year over year, combined, vs -19.2% for Lakeshore Biopharma Co Ltd. Lakeshore Biopharma Co Ltd's share of combined industry revenue moved from 0.01% to 0.01%, a gain of 0.00 percentage points.
Lakeshore Biopharma Co Ltd's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Lakeshore Biopharma Co Ltd | No | Yes | No | - |
| Competitors combined (15) | ||||
| Similar Growth & Profitability (8) | 0.00 % (0 of 8) | 87.50 % (7 of 8) | 0.00 % (0 of 8) | 16.70 % (1 of 6) |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
LSB Stock Performance relative to its Competitors
LSB Stock Performance relative to Similar Growth & Profitability Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Alto Neuroscience Inc | 282.9% | Outperformed |
| 2 | Definium Therapeutics Inc | 282.9% | Outperformed |
| 3 | Compass Pathways Plc | 282.9% | Outperformed |
| 4 | Indivior Pharmaceuticals Inc | 282.9% | Outperformed |
| 5 | Nrx Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Lakeshore Biopharma Co Ltd's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Lakeshore Biopharma Co Ltd's Comment on Competition and Industry Peers
Publicly Traded Peers of Lakeshore Biopharma Co Ltd
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Lakeshore Biopharma Co Ltd | 12.01 | 85.23 |
| Indivior Pharmaceuticals Inc | 4,573.12 | 1,333.00 |
| Definium Therapeutics Inc | 4,251.40 | - |
| Xenon Pharmaceuticals Inc | 3,657.67 | 13.17 |
| Ataibeckley Inc | 2,651.54 | 4.47 |
| Compass Pathways Plc | 1,786.58 | - |
| SUBTOTAL | 19,327.67 | 1,669.31 |
Sign in to see all competitors of Lakeshore Biopharma Co Ltd.
Sources: Lakeshore Biopharma Co Ltd's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Lakeshore Biopharma Co Ltd versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Lakeshore Biopharma Co Ltd's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Indivior Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Lakeshore Biopharma Co Ltd's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Lakeshore Biopharma Co Ltd | 12 | - | - |
| Indivior Pharmaceuticals Inc | 4,573 | 1,333,000 | 356,000 |
| Definium Therapeutics Inc | 4,251 | - | - |
| Xenon Pharmaceuticals Inc | 3,658 | 35,597 | -1,105,932 |
| Ataibeckley Inc | 2,652 | 22,144 | -3,308,347 |
| Compass Pathways Plc | 1,787 | - | -2,526,840 |
| PEERS TOTAL | 19,316 | 686,344 | -878,801 |
Sign in to see all peers for Lakeshore Biopharma Co Ltd.
Lakeshore Biopharma Co Ltd's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Lakeshore Biopharma Co Ltd's industry classification, broader than the peer set above. Market cap in millions of $.Lakeshore Biopharma Co Ltd ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Lakeshore Biopharma Co Ltd | 67 | 0.00 % |
Market cap and industry share for the rest of Lakeshore Biopharma Co Ltd's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-06-08.
Lakeshore Biopharma Co Ltd's Profitability & Cost Structure
Trailing 12-month margins from SEC-filed financials. Operating margin is compared to the Major Pharmaceutical Preparations industry median; gross margin, EBITDA margin and capital intensity are compared to the live industry average (341 companies).| Metric | Company | Industry | Difference |
|---|---|---|---|
| Gross Margin | - | 64.89 % (avg) | - |
| Operating Margin | -14.03 % | industry median | +56.9 pp |
| EBITDA Margin | - | -7.21 % (avg) | - |
| Capital Intensity (Capex / Revenue) | 2.90 % | 4.92 % (avg) | -2.0 pp |
Source: CSIMarket API, trailing 12 months. SG&A and R&D as a share of revenue have limited coverage as this data is backfilled and appear only where reported. Higher capital intensity is not inherently negative; it reflects the industry's asset requirements.
Lakeshore Biopharma Co Ltd's Strategic Group Map
Every company in Lakeshore Biopharma Co Ltd's industry and named-competitor list, plotted by trailing 12-month revenue growth and operating margin. Lakeshore Biopharma Co Ltd is shown in red; its closest peers by combined growth, margin and ROIC (the Similar Growth & Profitability group above) are labeled.
Source: CSIMarket API, trailing 12 months. Extreme outlier values (from near-zero-revenue companies) are excluded from the plotted cloud but never from the highlighted company or its labeled peers.
Lakeshore Biopharma Co Ltd's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Barriers to Entry | Lower than typical for the industry | Capital intensity (capex / revenue) of 2.90 % vs industry average 4.92 % (see Profitability & Cost Structure above) |
| Supplier Power | Not covered on this page | See Lakeshore Biopharma Co Ltd's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Lakeshore Biopharma Co Ltd's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Lakeshore Biopharma Co Ltd's Industry Attractiveness & Competitive Strength
A CSIMarket composite, not a standard field: each axis is an equal-weighted average of three factors already shown elsewhere on this page (industry growth, industry profitability and rivalry for attractiveness; relative market share, profitability and growth vs industry for strength). Disclosed as a designed methodology, not a precision measurement.
Lakeshore Biopharma Co Ltd falls in the Low attractiveness / Medium strength cell: Harvest.
Source: CSIMarket API, trailing 12 months. Each axis score is a simple 1(low)/2(medium)/3(high) average across its three inputs -- a transparent, disclosed simplification, not a validated academic scoring model.
Lakeshore Biopharma Co Ltd's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
- Operating margin 56.9 points above the industry median.
- Latest-quarter revenue run-rate is accelerating (+279.3% annualized vs trailing 12 months).
Weaknesses
- Return on equity 18.1 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (46.20 %) show financial-distress signals, a possible opening to gain share.
Threats
- Tracked peer group's revenue run-rate is broadly decelerating (-8.3% annualized).
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Lakeshore Biopharma Co Ltd's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Lakeshore Biopharma Co Ltd | 0.03 | 1.02 | 0.83 |
| Indivior Pharmaceuticals Inc | 0.29 | 0.84 | - |
| Definium Therapeutics Inc | 3.23 | 5.69 | 0.10 |
| Xenon Pharmaceuticals Inc | 5.87 | 18.75 | - |
| Ataibeckley Inc | 3.50 | 9.64 | 0.03 |
| Compass Pathways Plc | 1.28 | 1.47 | 0.48 |
Sign in to see all peers for Lakeshore Biopharma Co Ltd.
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Lakeshore Biopharma Co Ltd's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Lakeshore Biopharma Co Ltd | Q1 2024 | +5.5 % | - |
| Indivior Pharmaceuticals Inc | Q2 2026 | +13.6 % | +577.8 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | - |
| Ataibeckley Inc | Q2 2026 | +137.0 % | - |
| Compass Pathways Plc | Q2 2026 | - | - |
| PEERS TOTAL | +34.2 % | - |
Sign in to see all peers for Lakeshore Biopharma Co Ltd.
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Lakeshore Biopharma Co Ltd's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Lakeshore Biopharma Co Ltd | Q1 2024 | -10.0 % | -60.3 % |
| Indivior Pharmaceuticals Inc | Q2 2026 | -3.8 % | -61.1 % |
| Definium Therapeutics Inc | Q2 2026 | - | - |
| Xenon Pharmaceuticals Inc | Q2 2026 | - | +75.2 % |
| Ataibeckley Inc | Q2 2026 | - | - |
| Compass Pathways Plc | Q2 2026 | - | - |
Sign in to see all peers for Lakeshore Biopharma Co Ltd.
Lakeshore Biopharma Co Ltd's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Lakeshore Biopharma Co Ltd | - | - | - |
| Indivior Pharmaceuticals Inc | 28.21% | 68.79% | - |
| Definium Therapeutics Inc | - | - | - |
| Xenon Pharmaceuticals Inc | - | - | - |
| Ataibeckley Inc | - | - | - |
| Compass Pathways Plc | - | - | - |
Sign in to see all peers for Lakeshore Biopharma Co Ltd.
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Lakeshore Biopharma Co Ltd's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Lakeshore Biopharma Co Ltd | - | 0.14 |
| Indivior Pharmaceuticals Inc | 13.17 | 3.43 |
| Definium Therapeutics Inc | - | - |
| Xenon Pharmaceuticals Inc | - | 277.71 |
| Ataibeckley Inc | - | 592.79 |
| Compass Pathways Plc | - | - |
| PEERS AVERAGE | - | 11.58 |
Sign in to see all peers for Lakeshore Biopharma Co Ltd.
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.